View in EDS HTML Full Text PDF Full Text

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.

Saved in:
Bibliographic Details
Title: Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Authors: Sale MJ; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. matthew.sale@babraham.ac.uk., Minihane E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Monks NR; Oncology R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA., Gilley R; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Richards FM; Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Schifferli KP; Oncology R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA., Andersen CL; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Davies EJ; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Vicente MA; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, CB22 3AT, UK., Ozono E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Markovets A; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Dry JR; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Drew L; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Flemington V; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Proia T; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Jodrell DI; Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Smith PD; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK., Cook SJ; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. simon.cook@babraham.ac.uk.
Source: Nature communications [Nat Commun] 2019 Nov 14; Vol. 10 (1), pp. 5167. Date of Electronic Publication: 2019 Nov 14.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31727888
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sale+MJ%22">Sale MJ</searchLink>; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. matthew.sale@babraham.ac.uk.<br /><searchLink fieldCode="AU" term="%22Minihane+E%22">Minihane E</searchLink>; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.<br /><searchLink fieldCode="AU" term="%22Monks+NR%22">Monks NR</searchLink>; Oncology R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Gilley+R%22">Gilley R</searchLink>; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.<br /><searchLink fieldCode="AU" term="%22Richards+FM%22">Richards FM</searchLink>; Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.<br /><searchLink fieldCode="AU" term="%22Schifferli+KP%22">Schifferli KP</searchLink>; Oncology R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Andersen+CL%22">Andersen CL</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Davies+EJ%22">Davies EJ</searchLink>; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.<br /><searchLink fieldCode="AU" term="%22Vicente+MA%22">Vicente MA</searchLink>; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, CB22 3AT, UK.<br /><searchLink fieldCode="AU" term="%22Ozono+E%22">Ozono E</searchLink>; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.<br /><searchLink fieldCode="AU" term="%22Markovets+A%22">Markovets A</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Dry+JR%22">Dry JR</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Drew+L%22">Drew L</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Flemington+V%22">Flemington V</searchLink>; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.<br /><searchLink fieldCode="AU" term="%22Proia+T%22">Proia T</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Jodrell+DI%22">Jodrell DI</searchLink>; Pharmacology and Drug Development Group, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.<br /><searchLink fieldCode="AU" term="%22Smith+PD%22">Smith PD</searchLink>; Oncology R&D, AstraZeneca, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.<br /><searchLink fieldCode="AU" term="%22Cook+SJ%22">Cook SJ</searchLink>; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. simon.cook@babraham.ac.uk.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2019 Nov 14; Vol. 10 (1), pp. 5167. <i>Date of Electronic Publication: </i>2019 Nov 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31727888
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-019-12409-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5167
    Titles:
      – TitleFull: Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sale MJ
      – PersonEntity:
          Name:
            NameFull: Minihane E
      – PersonEntity:
          Name:
            NameFull: Monks NR
      – PersonEntity:
          Name:
            NameFull: Gilley R
      – PersonEntity:
          Name:
            NameFull: Richards FM
      – PersonEntity:
          Name:
            NameFull: Schifferli KP
      – PersonEntity:
          Name:
            NameFull: Andersen CL
      – PersonEntity:
          Name:
            NameFull: Davies EJ
      – PersonEntity:
          Name:
            NameFull: Vicente MA
      – PersonEntity:
          Name:
            NameFull: Ozono E
      – PersonEntity:
          Name:
            NameFull: Markovets A
      – PersonEntity:
          Name:
            NameFull: Dry JR
      – PersonEntity:
          Name:
            NameFull: Drew L
      – PersonEntity:
          Name:
            NameFull: Flemington V
      – PersonEntity:
          Name:
            NameFull: Proia T
      – PersonEntity:
          Name:
            NameFull: Jodrell DI
      – PersonEntity:
          Name:
            NameFull: Smith PD
      – PersonEntity:
          Name:
            NameFull: Cook SJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 11
              Text: 2019 Nov 14
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1